Dave brings to Thrive more than 25 years of diagnostics expertise in significant executive leadership roles in both startup and large-scale organizations. He currently serves as the Chief Executive Officer and Board Member for Thrive Earlier Detection. Prior to Thrive, he served as senior vice president and general manager of commercial operation for the Americas region at Illumina. There, Dave was responsible for all regional commercial functions, including sales, sales support, marketing, field service, technical support and field applications. Prior to joining Illumina, Dave was the chief commercial officer of Foundation Medicine, a company dedicated to transforming cancer care by identifying molecular alterations in each patient’s unique cancer and matching them with potential targeted therapies and immunotherapies. There, he led all commercial functions globally, including sales, marketing, client services, payer relations and medical affairs. Before that, Dave lead the oncology business unit at Life Technologies, responsible for the establishment of a clinical oncology strategy, centered on a central lab services model providing support to both research and clinical customers. After Thermo Fisher acquired Life Technologies, he transitioned to Thermo’s anatomic pathology division, where he oversaw all commercial operations globally.
Healthcare diagnostics is at the core of clinical decision making. Early diagnosis can increase the chances of a positive outcome, helping to improve the lives of patients and save payers the costs of further treatment. As health systems move from treatment to prevention, and from volume to value, diagnostics can accelerate this shift. Investment in innovative lab services and technologies is critical in enabling hospitals and healthcare systems to improve efficiencies in the lab, optimize their laboratories to realize gains, and deliver on the imperatives of improving patient outcomes while reducing costs. This session will provide insights from payers that have been actively investing in companies developing innovative lab services and technologies.